Loading travel map
- Travel
- Disease Prevalence
Top Destinations
View official travel advice and vaccine recommendations
Travel Advice by Smartraveller
This official travel advice is taken from the Smartraveller.gov.au website. For the latest and most complete information, please visit Smartraveller.gov.au
- Do not travel
- High level of caution
- Reconsider travel
- Normal safety precautions
- Unknown risk level
Disclaimer
Last update:
Travel advice for each country is provided by Smartraveller - https://smartraveller.gov.au
Vaccine recommendations provided by CDC - https://wwwnc.cdc.gov/travel/destinations/list
The Australian Immunisation Handbook
https://immunisationhandbook.health.gov.au/
This official travel advice is taken from the Smartraveller.gov.au website. For the latest and most complete information, please visit Smartraveller.gov.au
Travel advice by Smartraveller.
Last updated on
-
Transmitted Via
Disclaimer
Last update:
Travel advice for each country is provided by Smartraveller - https://smartraveller.gov.au
Vaccine recommendations provided by CDC - https://wwwnc.cdc.gov/travel/destinations/list
The Australian Immunisation Handbook
https://immunisationhandbook.health.gov.au/
Disease Prevalence
The diseases listed below represent travel-related vaccine-preventable diseases and malaria. Please note that these are not the only known disease risks prevalent in these countries.
Select a disease to reveal the risk level
Disease Risk Level
- High
- Medium
- Low
- No Data
Prevalence
- Country with known disease risk
- Country with no known or low disease risk
- No Data
Disclaimer
Last update:
Reference
leave-site-modal-text
You will now be leaving the site
You are now leaving campus.sanofi/au
Campus Sanofi Australia does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.
Campus Sanofi Australia makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Campus Sanofi Australia necessarily endorse such website and/or database.
The information the reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.
Waddling-Gait---Robert,-28-year-old-mild-LOPD-patient
Waddling Gait - Robert, 28-year-old mild LOPD patient
Reaching-Overhead---Robert,-28-year-old-mild-LOPD-patient
Reaching Overhead - Robert, 28-year-old mild LOPD patient
Standing-From-Sitting---Robert,-28-year-old-mild-LOPD-patient
Standing From Sitting - Robert, 28-year-old mild LOPD patient
Climbing-Stairs---Robert,-28-year-old-mild-LOPD-patient
Climbing Stairs - Robert, 28-year-old mild LOPD patient
Waddling-Gait---Karen,-18-year-old-moderate-LOPD-patient
Waddling Gait - Karen, 18-year-old moderate LOPD patient
Reaching-Overhead---Karen,-18-year-old-moderate-LOPD-patient
Reaching Overhead - Karen, 18-year-old moderate LOPD patient
Standing-From-Sitting---Karen,-18-year-old-moderate-LOPD-patient
Standing From Sitting - Karen, 18-year-old moderate LOPD patient
Climbing-Stairs---Karen,-18-year-old-moderate-LOPD-patient
Climbing Stairs - Karen, 18-year-old moderate LOPD patient
ASPIRE-ICT-1-23_Harrington_MAT-AU-2302788-1
ASPIRE-ICT-1-23_Kyle-Blakey_MAT-AU-2302789-1
Which-biologic-and-why--When-to-switch-to-another-one-
Waddling-Gait---Brian,-44-year-old-severe-LOPD-patient
Waddling Gait - Brian, 44-year-old severe LOPD patient
Reaching-Overhead---Brian,-44-year-old-severe-LOPD-patient
Reaching Overhead - Brian, 44-year-old severe LOPD patient
Standing-From-Sitting---Brian,-44-year-old-severe-LOPD-patient
Standing From Sitting - Brian, 44-year-old severe LOPD patient
Climbing-Stairs---Brian,-44-year-old-severe-LOPD-patient
Climbing Stairs - Brian, 44-year-old severe LOPD patient
RESP-ICT2_Wark_MAT-AU-2301970
RESP-ICT2_Wark_MAT-AU-2301970
RESP-ICT2_Stone_MAT-AU-2301972
RESP-ICT2_Stone_MAT-AU-2301972
Remission-in-rheumatology---Dr-Michelle-Tellus
Remission in rheumatology - Dr Michelle Tellus
Pavord_MAT-AU-2300571
Pavord_MAT-AU-2300571
Wark_MAT-AU-2300572
Wark_MAT-AU-2300572
Q-A-Discussion_MAT-AU-2300573
Q&A-Discussion_MAT-AU-2300573
RESP-ICT3_Tellus_MAT-AU-2302033
RESP-ICT3_Tellus_MAT-AU-2302033
RESP-ICT3_Lee_MAT-AU-2302034
RESP-ICT3_Lee_MAT-AU-2302034
RESP-ICT3_Hew_MAT-AU-2302035
RESP-ICT3_Hew_MAT-AU-2302035
Reduced-need-for-sinus-surgery
Up-to-45--of-severe-asthma-patients-have-comorbid-CRSwNP
Severe-asthma-with-comorbid-CRSwNP-leads-to-more-severe-disease
Less-rescue-oral-corticosteriod-use
Improved-sense-of-smell
Reduced-obstruction-and-congestion
Reduced-asthma-exacerbations-and-improved-lung-function
IL-4-and-IL-13-are-key-and-central-drivers-of-type-2-inflammation
Gaucher-diagnosis-1
RESP-ICT2_Debate_MAT-AU-2301973
RESP-ICT2_Debate_MAT-AU-2301973
RESP-ICT3_Q-A_MAT-AU-2302036
RESP-ICT3_Q&A_MAT-AU-2302036
ASPIRE-ICT1-23_Q-A_MAT-AU-2302791-1
RESP-ICT2_Stone_CS_MAT-AU-2301975
RESP-ICT2_Stone_CS_MAT-AU-2301975
RESP-ICT2_Wark_CS_MAT-AU-2301974
RESP-ICT2_Wark_CS_MAT-AU-2301974
RESP-ICT2_Panel-Discussion_MAT-AU-2301976
RESP-ICT2_Panel-Discussion_MAT-AU-2301976
SANA7993_Safety-Page-Tables_V0.2_1_New3
Products_Dermatology_Atopic-Dermatitis_Adverse-Events-Adults_18012021
Le-Cercle---Dr-Christophe-LEFEZ